Pediatrix Medical Group (NYSE:MD) Earns Outperform Rating from Analysts at Macquarie

Macquarie initiated coverage on shares of Pediatrix Medical Group (NYSE:MD) in a research note published on Monday, Marketbeat.com reports. The brokerage issued an outperform rating and a $18.00 target price on the stock.

MD has been the topic of a number of other research reports. StockNews.com raised Pediatrix Medical Group from a “hold” rating to a “buy” rating in a research report on Wednesday, December 11th. Deutsche Bank Aktiengesellschaft increased their target price on Pediatrix Medical Group from $9.00 to $15.00 and gave the stock a “hold” rating in a research note on Monday, November 4th. UBS Group lifted their target price on Pediatrix Medical Group from $10.50 to $16.50 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Jefferies Financial Group boosted their price target on shares of Pediatrix Medical Group from $14.00 to $18.00 and gave the stock a “buy” rating in a research note on Tuesday, November 5th. Finally, Truist Financial lifted their price objective on shares of Pediatrix Medical Group from $13.00 to $16.00 and gave the company a “hold” rating in a report on Monday, November 4th. Five analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $16.42.

Pediatrix Medical Group Stock Down 1.5 %

Shares of NYSE MD opened at $14.01 on Monday. The company has a market capitalization of $1.20 billion, a P/E ratio of -4.58, a P/E/G ratio of 2.00 and a beta of 1.57. The company has a debt-to-equity ratio of 0.83, a current ratio of 1.42 and a quick ratio of 1.42. The company has a 50 day simple moving average of $14.11 and a 200-day simple moving average of $10.90. Pediatrix Medical Group has a 1 year low of $6.62 and a 1 year high of $16.41.

Pediatrix Medical Group (NYSE:MD) last posted its earnings results on Friday, November 1st. The company reported $0.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.37 by $0.07. The company had revenue of $511.20 million during the quarter, compared to analysts’ expectations of $498.87 million. Pediatrix Medical Group had a positive return on equity of 12.79% and a negative net margin of 12.65%. The firm’s quarterly revenue was up .9% compared to the same quarter last year. During the same quarter last year, the firm earned $0.29 earnings per share. On average, equities research analysts predict that Pediatrix Medical Group will post 1.26 earnings per share for the current year.

Insider Activity at Pediatrix Medical Group

In related news, EVP Mary Ann E. Moore sold 8,108 shares of the stock in a transaction on Friday, November 8th. The stock was sold at an average price of $16.00, for a total value of $129,728.00. Following the transaction, the executive vice president now owns 135,810 shares of the company’s stock, valued at $2,172,960. This represents a 5.63 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Mark S. Ordan sold 27,600 shares of the firm’s stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $15.35, for a total value of $423,660.00. Following the completion of the sale, the director now owns 138,683 shares in the company, valued at approximately $2,128,784.05. This represents a 16.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.00% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Pediatrix Medical Group

Several institutional investors have recently added to or reduced their stakes in MD. Quest Partners LLC raised its stake in shares of Pediatrix Medical Group by 25.6% during the third quarter. Quest Partners LLC now owns 3,054 shares of the company’s stock worth $35,000 after purchasing an additional 622 shares during the last quarter. nVerses Capital LLC purchased a new position in Pediatrix Medical Group during the 2nd quarter worth $31,000. Innealta Capital LLC acquired a new stake in shares of Pediatrix Medical Group in the 2nd quarter worth $33,000. Quarry LP boosted its holdings in shares of Pediatrix Medical Group by 54.1% in the third quarter. Quarry LP now owns 4,735 shares of the company’s stock valued at $55,000 after acquiring an additional 1,662 shares in the last quarter. Finally, Nisa Investment Advisors LLC boosted its holdings in shares of Pediatrix Medical Group by 47.2% in the second quarter. Nisa Investment Advisors LLC now owns 4,755 shares of the company’s stock valued at $36,000 after acquiring an additional 1,524 shares in the last quarter. Hedge funds and other institutional investors own 97.71% of the company’s stock.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.